VITARINE'S INITIAL PUBLIC OFFERING IS POSTPONED
VITARINE'S INITIAL PUBLIC OFFERING IS POSTPONED pending completion of FDA's inspection of the company's St. Croix, Virgin Islands manufacturing facility. "The postponement was requested by the company in order to enable senior management to clarify issues that have arisen in connection with the accuracy of certain documents relating to a product application at its St. Croix plant," Vitarine said in a recent statement. Vitarine's facility in St. Croix is under active investigation by FDA, according to the agency. Reportedly, the company does not have any generic antibiotic applications pending at FDA that could be held up by the investigation. According to Vitarine's recent prospectus, a Virgin Islands subsidiary "owns two buildings aggregating approximately 20,000 square feet located in St. Croix." The filing notes that "since April 1987, one building has been used solely for the purpose of manufacturing cephalosporins [and] since 1987, the company has spent approximately $123,000 in improving the second building to be available for the manufacture of other products." The document adds that production of the "other products" began in September 1988. Vitarine hopes to raise between $18.7 mil. and $22.1 mil. from the 1.7 mil. share initial public offering, based on an offering price of between $11 and $13 a share. Proceeds from the offering will go towards eliminating debt taken on during Vitarine's acquisition of six regional generic drug distributors last year. The distributors were purchased at a total price of $53.4 mil.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth